Remove tag quality-life
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

Currently, most patients face the prospect of life-long treatment with MS medications, as the main objectives of available disease-modifying therapies (DMTs) are to reduce the frequency of relapses and to delay the accumulation of disability. DMTs for MS have a high price tag, particularly in the US.

Marketing 246
article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. ICER uses quality-adjusted life year (QALY), a cost effectiveness metric to measure the value of a healthcare intervention.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)

Rethinking Clinical Trials

Criteria included essential workers (25% increased odds of drug allocation), patients with an area of deprivation index score 80-100 (25% increased odds), end-of-life prognosis, defined as greater than 50% chance of death within one year from underlying conditions (50% decreased odds). Many patients did not answer the phone.

article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. They also require better mechanisms for managing IO-related toxicities and improving patients’ quality of life (QOL). Cost-related unmet needs also scored highly.

article thumbnail

Blue Note leukaemia DTx gets FDA breakthrough tag

pharmaphorum

He is the principal investigator for a clinical study that will evaluate the impact of BNT200 on quality of life, mood, and symptoms of patients diagnosed with AML. The post Blue Note leukaemia DTx gets FDA breakthrough tag appeared first on. Other DTxs are aimed at people being treated for breast and lung cancers.

article thumbnail

Grand Rounds December 2, 2022: A Randomized Controlled Trial of Mobile Health Intervention in Heart Failure and Diabetes: Lessons Learned (G. Michael Felker, MD, MHS)

Rethinking Clinical Trials

In patients with both heart failure and diabetes, the 3-month mHealth intervention significantly improved daily volitional physical activity as measured by step counts; health related quality of life as measured by KCCQ, and metabolomic profiles of peripheral blood. This trial turned out to be more challenging than anticipated.

Trials 130
article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

“Digitally native brands are typically agile businesses from the ground up, and agility and flexibility are part of their core makeup,” says Joe Holmes, vice president, marketing services, US at Tag. Jeremy Richter, Tag. Joe began his life at Tag in the UK, bringing efficiencies to his clients, working across all conceivable channels.

Branding 119